DOD Prostate Cancer Clinical Trial Award

The summary for the DOD Prostate Cancer Clinical Trial Award grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.

DOD Prostate Cancer Clinical Trial Award: The PCRP Clinical Trial Award mechanism was introduced in FY01. Since then, 71 proposals have been received and 16 have been recommended for funding. The Clinical Trial Award supports rapid execution of Phase 0/I, Phase I, Phase I/II, or Phase II clinical trials with the potential to have a significant impact on prostate cancer prevention, detection, diagnosis, or treatment. Studies in a broad range of areas related to prostate cancer clinical management and care will be accepted under this mechanism, including but not limited to: . Evaluations of novel drugs, biologics, or devices . Survivorship . Diet . Quality of life . Psychosocial interventions . Behavioral studies Exploratory clinical trials (Phase 0) may be submitted, but they must be accompanied by a Phase I clinical trial (Phase 0/I). PIs must clearly specify in their proposals which type of clinical trial, Phase 0/I, Phase I, Phase I/II, or Phase II, is being proposed. Please refer to http://www.clinicaltrials.gov/ for definitions and descriptions of each type of clinical trial. Each proposal must include only one clinical trial. PIs are encouraged to pursue correlative studies that accompany their trials. PIs conducting correlative studies must describe in detail the study aims, procedures or methods, and plans for data management and analysis, including an appropriately powered statistical plan. It is expected that the intervention, drug, or device to be used in the proposed trial will be available in sufficient quantities and ready for clinical trials at the time that the award is made. Further, it is expected that the clinical trial will be initiated within 12 months of the award date. Note that Investigational New Drug (IND)/Investigational Device Exemption (IDE) approvals, if applicable, should be in process or completed before submission of an application to this mechanism. If IND/IDE approval is not received by April 30, 2009, the Government reserves the right to not fund the award. Funding from this award mechanism cannot be used for preclinical research studies.